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Polypyrrole nanoparticles for tunable, pH-sensitive
and sustained drug release
Devleena Samanta,a Jana L. Meisera,b and Richard N. Zare*a
We report the development of a generalized pH-sensitive drug delivery system that can release any
charged drug preferentially at the pH range of interest. Our system is based on polypyrrole nanoparticles
(PPy NPs), synthesized via a simple one-step microemulsion technique. These nanoparticles are highly
monodisperse, stable in solution over the period of a month, and have good drug loading capacity
(∼15 wt%). We show that PPy NPs can be tuned to release drugs at both acidic and basic pH by varying
the pH, the charge of the drug, as well as by adding small amounts of charged amphiphiles. Moreover,
these NPs may be delivered locally by immobilizing them in a hydrogel. Our studies show encapsulation
within a calcium alginate hydrogel results in sustained release of the incorporated drug for more than
21 days. Such a nanoparticle-hydrogel composite drug delivery system is promising for treatment of long-
lasting conditions such as cancer and chronic pain which require controlled, localized, and sustained drug
release.
Introduction
One of the main challenges in drug delivery is to ensure loca-
lized and controlled release of drugs to minimize side eﬀects
and increase drug eﬃcacy. This control can be attained by
using so called “smart materials” that respond to an external
stimulus, thereby releasing their payload. Several drug delivery
systems (DDSs) have been developed that release drugs caused
by pH change,1,2 magnetic field,3–5 enzymes,6,7 oxidation/
reduction,8,9 light,10 temperature,11 ultrasound12,13 and electri-
cal stimuli.14–17 Out of these, one of the heavily
investigated release systems depends on pH change as it does
not require any external stimulus. The inherent pH in
diﬀerent parts of the body varies, but remains locally rather
constant. For example, the pH varies widely in diﬀerent parts
of the gastrointestinal tract: pH 1–3 in the stomach, pH 5 in
the small intestine and pH 7–8 in the colon.2 Sites of inflam-
mation, bacterial infections or tumors have also been found to
be more acidic (∼pH 5–6.5) than physiological
pH (∼pH 7.4).18–20
The use of nanoparticles (NPs) in devising pH-based DDSs
is appealing because of several reasons. NPs have a large
surface-to-volume ratio, and therefore, the amount of drug
that can be loaded in them is increased. Owing to their small
size, they can be circulated in the body without causing any
blockage, and delivered through the lymphatic system.21 NPs
also facilitate delivery of hydrophobic and poorly bioavailable
drugs,22 and can protect drugs from degradation until they
reach their target site.23,24
Most pH-sensitive drug carriers are based on polyelectro-
lytes with acidic (carboxylic acids, sulfonic acids, phosphoric
acids) or basic (amines) ionizable moieties.25,26 These groups
can either accept or release protons, thereby causing confor-
mation changes that lead to drug release. Carriers containing
acid-cleavable bonds27,28 are also common. Some examples
of pH responsive systems include DDSs based on pH-sensitive
micelles,29 liposomes,30 hydrogels,31 peptides,32 and hybrid
organic–inorganic nanostructures.33 Most of these systems can
only release drugs above or below a certain pH. That is, there
is no universal system that can selectively release drugs both at
high and low pH, on a case by case basis. In this paper,
we report the investigation of polypyrrole nanoparticles
(PPy NPs) for devising such a versatile DDS.
PPy is an electrically conducting polymer which is both bio-
compatible and nontoxic.34,35 It has been studied in detail
for developing DDSs based on electrical stimulation.14–17,36,37
However, the pH-sensitive behavior of PPy has received less
attention for the purposes of drug delivery. Recently, Wang
et al.38 have shown that hollow PPy nanocapsules loaded with
antitumor agent doxorubicin (DOX) are pH-sensitive, and
release more than half of the encapsulated drug within 15 h at
a pH of 4.5. They have also shown that the amount of release
can be further increased by applying near infrared light. Park
et al.39 have studied PPy nanoparticles doped with hyaluronic
acid for preferential release of DOX at lysosomal pH (pH < 5).
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The mechanism of drug release from PPy NPs has not yet been
investigated in detail.
In this work, we have synthesized polypyrrole nanoparticles
(PPy NPs) without the use of dopants. We have loaded these
PPy NPs with fluorescein sodium salt (FL), a negatively
charged model drug, and rhodamine 6G (R6G), a positively
charged model drug. We have studied the release character-
istics of these two systems to understand the general mechan-
ism of charged drug release from PPy NPs at desired pH. The
pH responsiveness of our DDS can be used to take drugs
orally. Also, these NPs can be delivered locally via a hydrogel
in the treatment of diseases that need repeated doses such as
chronic pain, cancer, diabetes, etc. To show this, we have
studied piroxicam (PX), a nonsteroidal anti-inflammatory drug
used in the treatment of rheumatoid arthritis. We have dis-
persed PX-loaded PPy NPs in a calcium alginate (CaAlg) hydro-
gel and monitored the sustained release of PX. Fig. 1 presents
a schematic of this drug delivery system. It should be noted
that our system is not optimized for a particular drug. Instead,
we explore the potential of PPy NPs for pH-sensitive and sus-
tained drug delivery, with a focus on understanding the chief
parameters that aﬀect drug release.
Materials
Pyrrole (reagent grade, 98%), sodium dodecyl sulfate (Reagent-
Plus®, ≥98.5%), 35 wt% hydrogen peroxide H2O2, piroxicam
(>98%), fluorescein sodium salt, Trizma® hydrochloride buﬀer
solution, TRIS-HCl buﬀer solution, Pur-A-Lyzer™ Dialysis Kits,
Whatman® Anotop® 25 syringe filters, alginic acid sodium
salt, calcium chloride (ReagentPlus®, 99.99%), and BD Falcon
cell strainer (40 μm, Nylon) were purchased from Sigma
Aldrich. Rhodamine 6G was purchased from Lambda Physik.
Fig. 1 Schematic of the drug delivery system: (a) synthesis of the drug-loaded nanoparticles; (b) pH-triggered drug release; and (c) sustained
release from a hydrogel containing embedded drug-loaded nanoparticles.
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Synthesis of drug-loaded polypyrrole nanoparticles
All reactions and measurements were carried out in triplicate
and at room temperature unless mentioned otherwise. In a
typical synthesis, 144.2 mg of SDS were dissolved in 5 mL of
40 mM HCl solution. To this, 15 mg of the drug FL, PX or R6G
were added and stirred with heating, if necessary, till complete
dissolution. Then 100 µL pyrrole were added, followed by 200 µL
35 wt% hydrogen peroxide (H2O2). The solution started to
darken immediately and turned black within 10 min after the
addition of H2O2. The solution was stirred for 24 h to ensure
complete yield of drug-loaded polypyrrole nanoparticles.
Washing the nanoparticles
3 mL of the reaction mixture were washed using dialysis tubes
(MWCO 3.5 kDa). The unwashed nanoparticles were placed in
the dialysis tubes and the tubes were then immersed in
150 mL water (supernatant). The water was stirred for 24 h.
The washed nanoparticles were transferred to a 15 mL
centrifuge tube and the volume was adjusted to 6 mL with
water. These nanoparticles were then stored under ambient
conditions.
Calculation of drug loading
The drug loading was determined from the supernatant of the
washing using the method of standard addition. 200 µL of the
supernatant were placed in a Greiner flat-bottomed 96 well-
plate. The well plate was read using a TECAN infinite M1000
plate reader. The UV-Vis spectrum was monitored between
250–500 nm for PX and 400–700 nm for FL and R6G, and read-
ings were taken by adding 0, 10, 20, 30 and 40 µL of 50 µg
mL−1 standard solution of the compound in water. The absor-
bance maxima were plotted as a function of the concentration
of the added standard drug/drug model. The data points were
fit by least squares to a straight line, and the x-intercept of the
regression line gave the initial concentration of the drug/drug
model in the wash.
Size and stability measurements
The size distribution of the nanoparticles was measured
using dynamic light scattering (DLS) using a Malvern Zetasizer
Nano ZS90 instrument. The washed nanoparticles were also
imaged using scanning electron microscopy (SEM). For DLS,
5 µL of the washed nanoparticles were diluted with 2 mL of
water and vortexed. The DLS reading was taken using 1 mL of
the resultant solution. The number of measurements was
set to 15. For SEM, 20 µL of the washed solution were
placed on an aluminum SEM stub and dried overnight in a
vacuum desiccator. The sample was then sputter coated,
and the images were recorded with a Zeiss Sigma FESEM
instrument.
To measure the stability of the nanoparticles, the size distri-
bution of the nanoparticles was monitored over a period of 28
days using DLS. The zeta potential was also measured during
that period of time by taking 10 µL of the nanoparticles and
diluting them with 1 mL water. We found that the nano-
particles are essentially unchanged when stored at room tem-
perature for a period of three months.
pH-triggered release
80 µL of the washed nanoparticles and 80 µL of water were
added to a 2 mL centrifuge tube. 1.44 mL of solution of appro-
priate pH were added to make a total volume of 1.6 mL. The
solutions of diﬀerent pH used were 0.01 M HCl (pH 2), 10−5 M
HCl (pH 5), Trizma® hydrochloride buﬀer solution (pH 7.4),
and 0.01 M TRIS-HCl (pH 8.0). Additionally, 1 M HCl, 2 M HCl
and 3 M HCl solutions were used for R6G. Each resultant solu-
tion was vortexed for 10 s and filtered through 0.02 μm syringe
filters. The R6G filtrate from 1 M HCl, 2 M HCl and 3 M HCl
solutions were neutralized by adding NaOH. To measure the
eﬀect of surfactant concentration at a fixed pH (7.4), a similar
procedure was followed. In this case, instead of 80 µL of water,
16 µL and 32 µL of 100 mM SDS/DTAB were added to yield
solutions with a final surfactant concentration of 1 mM and
2 mM in SDS/DTAB, respectively. The total volume was
adjusted to 1.6 mL with water.
150 µL of the filtrate (100 µL for FL) were placed in each of
4 wells in a 96-well plate. 0, 10, 20, 30 µL of 50 µg mL−1 stan-
dard drug solution (5 µg mL−1 used for R6G) in water were
added to the 4 wells respectively. The total volume was
adjusted to 180 µL (130 µL for FL). The UV-Vis spectrum was
recorded between 250–500 nm for PX and 400–700 nm for FL
and R6G. The concentration of the drug in solution was found
out using the method of standard addition as described above.
Sustained release of PX
750 µL of the PX-PPy NPs were dispersed in equal volume of
1% sodium alginate solution. The NP–alginate mixture was
added to a cell strainer with 40 µm pores while it was soaked
in 0.5 M calcium chloride. The calcium alginate (CaAlg) gel
formed immediately as the alginate came into contact with
Ca2+ ions. The cell strainer was then washed twice with 5 mL
of water and placed in a 20 oz. glass vial. 10 mL of distilled
water and a magnetic stir bar were added to this. The solution
was replaced every day and the study was continued for 3
weeks. The absorbance of the solution was monitored every
day. This experiment was replicated 5 times. The purpose of
the cell strainer was to contain the hydrogel in place so that
the spinning stir bar did not disintegrate the gel on impact.
The pores were suﬃciently high to allow free diﬀusion across
the cell strainer. As a control, to prove that the release of PX is
slowed primarily by the PPy NPs and not by the hydrogel, the
experiment was repeated with the same amount of free PX as
in the PPy NPs, dispersed in a bare CaAlg hydrogel.
Results and discussion
Synthesis of stable polypyrrole nanoparticles
The polypyrrole nanoparticles (PPy NPs) were synthesized by
oxidative polymerization of pyrrole in an acidic micellar
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solution of sodium dodecyl sulfate (SDS). In 0.04 M HCl solu-
tion, SDS was dissolved to reach a concentration of 0.1 M (criti-
cal micellar concentration, CMC, of SDS in this environment is
3.3 mM (ref. 40)), followed by the dissolution of the com-
pounds FL, PX and R6G, and pyrrole. The oxidation of pyrrole
was initiated by the addition of H2O2. The mechanism of PPy
formation using this synthetic route has been studied and is
reported in literature.40 Most chemical syntheses of PPy
involve strong oxidizing agents such as ferric chloride, potas-
sium dichromate, ammonium persulfate, potassium permanga-
nate, etc. which leave traces of these toxic materials embedded
into the polymer matrix.40,41 The use of H2O2 avoids these
complications and is, therefore, more suitable for biomedical
applications. Moreover, we chose this synthesis route as other
methods do not give such small nanoparticles,36 and the nano-
particles tend to aggregate over time, attested by discrepancies
between the size measured using DLS and that measured by
SEM.36
After 24 h of stirring, the nanoparticles were dialyzed for
another 24 h in water to remove impurities and loosely bound
drug molecules. The loading was calculated in terms of weight
percentage with respect to the amount of compound initially
added as well as the amount of pyrrole initially added. Almost
all of the compounds added was incorporated into PPy
(99.9% for FL, 97.7% for PX, and 100% for R6G). By weight of
pyrrole, the loading was ∼15% for each compound. This
is about a four-fold increase in loading capacity compared
to that of FL-loaded PPy NPs synthesized by another
chemical method reported before.36 This figure might also be
compared with that achieved by Park et al.39 who reported a
6.5% loading of doxorubicin onto PPy NPs doped with hyaluro-
nic acid.
As a measure of stability, the zeta potential and the size
of the nanoparticles were monitored over the period of a
month. The purpose of this study was to ensure that the nano-
particles can be stored in solution, bypassing the need for
drying and redispersing them. It is assumed that as long
as the drug is attached to the PPy, it will not degrade.42 PPy
NPs are known to have a positively charged backbone resulting
from overoxidation.40 Fig. 2 shows the zeta potential of the
PPy NPs. For all compounds, irrespective of their charges,
the surface charge of the nanoparticles is negative and
less than −30 mV. This fact can be understood by realizing
that the adsorption of excess negatively charged SDS molecules
gives the nanoparticles an overall negative charge. As expected,
the zeta potential is less negative when a positively
charged compound (R6G) is loaded. The strongly negative
zeta potential suggests that the particles should not aggregate
over time. This expected behavior is verified by size measure-
ments (Fig. 3) performed by DLS. The average DLS size of
the nanoparticles is about 34 nm, 43 nm and 28 nm for
FL-, PX- and R6G-loaded PPy, respectively. These results
are consistent with SEM images of these nanoparticles
(Fig. 4). Both zeta potential and size are fairly constant
over time, attesting to the inherent stability of these
nanoparticles.
Tuning pH-sensitive drug release
The release of the compounds from the PPy NPs was tested
in vitro at four diﬀerent biologically relevant pH, namely, pH 2,
pH 5, pH 7.4, and pH 8. For this purpose, a small amount of
the PPyNPs was added to a solution of the appropriate pH.
The mixture was vortexed and the PPy NPs were removed by fil-
tration. The amount of compound in the filtrate was moni-
tored using UV-Vis spectroscopy. The absorption profiles of all
the molecules studied here are sensitive to their environment.
For example, the absorption maxima for FL shifts to shorter
wavelengths at lower pH. The molar extinction coeﬃcient also
decreases.43,44 Similarly, the absorbance of PX and R6G also
depend on the surrounding media.45 Therefore, to account for
matrix eﬀects, a standard addition method was employed to
quantify the release.
We observed that for FL, which is a negatively charged
model drug, increase in pH increases drug release (Fig. 5).
Intuitively, we expected the reverse to be true in case of R6G,
Fig. 3 Sizes of PPy NPs measured by DLS. Uncertainties are one stan-
dard deviation (3 measurements).
Fig. 2 Zeta potential of PPy NPs. Uncertainties are one standard devi-
ation (3 measurements).
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which is positively charged. However, we could not detect any
absorbance peak for R6G at the diﬀerent biological pH tested.
We hypothesized that it is possible that as lower pH should
favor R6G release, environment more acidic than pH 2 might
be necessary. To test our hypothesis, we tried three more
release media: 1 M HCl, 2 M HCl, and 3 M HCl. As shown in
Fig. 6, the release of R6G increases with increasing acidity of
the solution. Like FL, PX is also negatively charged, and its
release behavior is analogous to that of FL (Fig. 5). Please note
that the data presented in Fig. 5 and 6 represent the
percentage release of the drug after only 10 s of vortexing the
nanoparticles in the relevant pH solutions. Higher release per-
centages are expected to occur from the nanoparticles when
more equilibration time is allowed or under sink conditions.
Given that our system is not optimized for any particular drug,
the trends in drug release are more important than their exact
magnitudes.
Mechanism of pH-triggered drug release
The reported protonation pKa of PPy is 2–4,
46 and as prepared,
PPy is partially protonated.40,46 A more detailed mechanism of
protonation and deprotonation of PPy can be found else-
where.46,47 In our case, the more acidic the pH, the more the
protonation of PPy, and hence, more negatively charged com-
pound can be associated with it. Higher pH favors more depro-
tonation of PPy and lowers the overall positive charge. This
seems to facilitate the release of negatively charged drug cargo.
In case of a positively charged drug, lower pH increases the net
positive charge on the PPy backbone and therefore causes
electrostatic repulsion that pushes out the drug. The strong
binding of positively charged R6G to the positively charged
PPy suggests that both electrostatic and hydrophobic inter-
actions are involved in the interaction between compound and
PPy. It is reasonable to believe that the adsorbed SDS on the
surface of PPy also plays an important role in both compound
attachment and detachment from PPy. It probably helps to
mitigate same charge repulsions between PPy and R6G.
If pH were the only parameter that governs drug release,
this PPy-based DDS may not be appropriate for delivering posi-
tively charged drugs, because like R6G, other positive drugs
would also possibly bind too strongly to the NPs. Given that
the release mechanism arises from changes in surface charge,
the addition of small amounts of surfactants should also
modify the release.
From Fig. 7, we can clearly see this variation in release
when SDS and dodecyltrimethylammonium bromide (DTAB)
Fig. 4 SEM images of (a) FL-PPy, (b) PX-PPy, and (c) R6G-PPy.
Fig. 5 Release of FL and PX from PPy NPs. Uncertainties are one stan-
dard deviation (3 measurements).
Fig. 6 Release R6G from PPy NPs. Uncertainties are one standard devi-
ation (3 measurements).
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are added at a constant pH of 7.4. SDS, being negatively
charged, increases release of FL and PX. On the contrary,
DTAB, being positively charged, decreases their release. In con-
trast, DTAB increases the release of R6G. The amount of
release scales with the amount of surfactant added. This be-
havior is probably because the additional surfactants attach or
move to the surface of the NPs. In case of similarly charged
compounds, the surfactants compete with binding and push
out more of the compound. Compounds of opposite charge
are held more strongly electrostatically. In our study we have
employed 1 mM and 2 mM surfactant concentrations
which are below the CMC of both surfactants. Above the
CMC, diﬀerent surfactants can aggregate diﬀerently,48,49 and
the release under those circumstances would be more
complicated.
Encapsulation in a hydrogel for sustained release
For testing local delivery of the PPy NPs, we dispersed the
PX-PPy NPs in a calcium alginate (CaAlg) hydrogel. PX is a
hydrophobic pain medication with poor bioavailability. Given
that the half-life of this drug is about 30 h,50 it would be
beneficial to have this compound delivered in an extended
manner, particularly for patients with chronic pain. The hydro-
gel was prepared by the addition of sodium alginate solution
containing the PPy NPs to a solution of calcium chloride.
Contact between these two solutions immediately leads to the
formation of the gel, as the Ca2+ ions start cross-linking the
alginate molecules. The release of PX was monitored over the
period of three weeks (Fig. 8). We observed that the release is
very slow, and only ∼19% of the incorporated PX is released in
this time. In comparison, the majority of existing sustained
release formulations of PX release a significant portion of the
encapsulated drug (between 60–80%) within a few hours.51,52
Without the PPy NPs, 94% of the same amount of PX dis-
persed in bare CaAlg hydrogel is released within 5 days
(Fig. 9). Our results show that the diﬀusion of PX is inhibited
primarily by the PPy NPs, and not the hydrogel. It should be
mentioned that the release can also be modified by varying
the proportions of Ca2+ ions and alginate.53 Elevated concen-
trations of Ca2+ ions increase the cross-linking of the hydrogel,
and therefore, decelerate the release.53
Conclusions
We have synthesized stable, monodisperse PPy NPs with a
drug loading capacity as much as 15% by weight, and showed
that these NPs can be used as a versatile drug delivery platform
for releasing both positively and negatively charged drugs. The
drug release can be triggered by a change in pH and can be
fine-tuned by addition of small amounts of surfactant to the
NPs. In general, negatively charged drugs are released more at
higher pH and positively charged drugs are released more at
lower pH. This system might be particularly important in the
treatment of cancer, given that anti-cancer drugs of the anthra-
Fig. 7 Eﬀect of surfactants at diﬀerent concentrations on drug release
at constant pH (7.4). Uncertainties are one standard deviation
(3 measurements).
Fig. 8 Sustained release of PX from PPy NPs. Uncertainties are one
standard deviation (5 measurements).
Fig. 9 Comparison between PX release from bare CaAlg hydrogel (solid
squares) and from PPy NPs dispersed in CaAlg (solid dots). Uncertainties
are one standard deviation (3 measurements for bare hydrogel and
5 measurements for PX-PPy NPs in hydrogel).
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cycline family such as doxorubicin, daunorubicin, etc. are
positively charged,36,39 and would be preferentially released in
more acidic cancerous tissue. Other diseases that either occur
in parts of the body that have a pH diﬀerent from the physio-
logical pH or cause the local pH to change from 7.4 can also
benefit from such a DDS. Moreover, these nanoparticles are
promising as sustained release vehicles.
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